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Abstract
Introduction: Neutrophils and monocytes play an important role in overt inflammation in chronic inflammatory joint 
diseases such as rheumatoid arthritis (RA). The sympathetic nervous system (SNS) inhibits many neutrophil/monocyte 
functions and macrophage tumor necrosis factor (TNF), but because of the loss of sympathetic nerve fibers in inflamed 
tissue, sympathetic control is attenuated. In this study, we focused on noradrenergic and TNF regulation of human 
neutrophil peptides 1-3 (HNP1-3), which are proinflammatory bactericidal α-defensins.
Methods: Synovial tissue and cells were obtained from patients with RA and osteoarthritis (OA). By using 
immunohistochemistry and immunofluorescence, HNP1-3 were tracked in the tissue. With synovial cell-culture 
experiments and ELISA, effects of norepinephrine, TNF, and cortisol on HNP1-3 were detected.
Results: HNP1-3 were abundantly expressed in the synovial lining and adjacent sublining area but not in deeper layers 
of synovial tissue. The human β-defensin-2, used as control, was hardly detectable in the tissue and in supernatants. 
HNP1-3 double-stained with neutrophils but not with macrophages, fibroblasts, T/B lymphocytes, and mast cells. 
Norepinephrine dose-dependently decreased HNP1-3 levels from RA and OA cells. TNF also inhibited HNP1-3 levels 
from OA but not from RA cells. Cortisol inhibited HNP1-3 levels only in OA patients. A combination of norepinephrine 
and cortisol did not show additive or synergistic effects.
Conclusions: This study demonstrated an inhibitory effect of norepinephrine on HNP1-3 of mixed synovial cells. In 
light of these findings, the loss of sympathetic nerve fibers with low resting norepinephrine levels might also augment 
the inflammatory process through HNP1-3.
Introduction
Rheumatoid arthritis (RA) is a chronic joint disease lead-
ing to severe erosions of adjacent bone, which are not
observed in patients with osteoarthritis (OA). Although
an inflammatory process is present in OA synovial tissue,
RA patients demonstrate a higher state of synovial tissue
inflammation compared with OA patients. In the
pathophysiology of RA, T cells, B cells, macrophages,
fibroblasts, and osteoclasts play dominant roles. In addi-
tion, neutrophils are important mediators of tissue
inflammation in RA, and neutrophils are the most abun-
dant cell type in the synovial fluid [1]. Neutrophil produc-
tion of proteases, reactive oxygen species, S100 proteins,
cytokines, chemokines, and complement stimulate
inflammation [2]. Fc-gamma receptors on neutrophils
can bind immune complexes that can perpetuate the
inflammatory process [2]. In addition, neutrophils pro-
duce important antimicrobial proteins, such as defensins
[3].
A large number of defensins and defensin-like peptides
have been reported in many organisms. As of March
2010, 363 entries had been recorded in a defensin data-
base [4]. One distinguishes α-defensins (in neutrophils)
from β-defensins (in other cells). Human neutrophils
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Page 2 of 9contain four α-defensins (HNP-1 to HNP-4) [5]. HNPs
are unique to neutrophils and account for ~99% of the
total α defensin content of these cells [5]. HNPs exert
chemotactic, immunomodulating, and cytotoxic effects
and participate in inflammation [5]. In contrast, human
β-defensins have been described mainly in epithelial cells
but also in leukocytes, heart, skeletal muscle, testis, kera-
tinocytes, tonsil, placenta, and other tissues [4].
Defensins are expressed and released on bacterial stimuli
involving the Toll-like receptors and, in addition, other
stimuli, such as cytokines [6]. Besides microbicidal activi-
ties, defensins can stimulate TNF secretion from mac-
rophages, as recently reported [7].
In tissues of patients with RA and OA, the investigation
of defensins has recently begun. One report demon-
strated the presence of HNP1 3 positive cells in synovial
tissue of healthy subjects and in patients with suppurative
arthritis, osteoarthritis (OA), and RA [8]. However, regu-
lation of HNP1-3 in these diseases (for example, by
cytokines) has not yet been investigated. Another report
found an association of HNP1-3 in synovial fluid of
patients with RA and severe erosive joint disease [9].
These studies clearly demonstrate that neutrophil
defensins are present in inflamed tissues of patients with
RA and OA. Some reports also demonstrated that
defensins can be produced by dendritic cells and mono-
cytes [10,11], but this has not been demonstrated in syn-
ovial tissue or cells of RA and OA patients.
For several years, we have been interested in the role of
the sympathetic nervous system (SNS) in OA, RA, and
experimental arthritis [12,13]. We have been attracted by
effects of the SNS on neutrophils and monocytes, but
effects on defensin secretion are presently not known. It
is recognized that activation of the SNS enhances neutro-
phil and monocyte mobilization, leading to increased
numbers of circulating neutrophils and monocytes,
called the first line of defense [14-16]. Such a mechanism
might increase the numbers of neutrophils and mono-
cytes that enter inflamed tissue at sites of leaky endothe-
lial structures (leakiness is important because
catecholamines inhibit neutrophil and monocyte attach-
ment to normal endothelium). However, once neutro-
phils and monocytes have entered inflamed tissue, the
major neurotransmitter of sympathetic nerve fibers, nor-
epinephrine, inhibits several neutrophil and monocyte
functions. For example, norepinephrine decreases migra-
tion [17,18], oxygen radical production [19], phagocytosis
[18], and bactericidal activity [20]. These inhibitory influ-
ences were present only when norepinephrine appeared
at high concentrations (via β2-adrenergic receptors). This
might be quite different at low concentrations when nor-
epinephrine exerts its effects via α-adrenoceptors [21-
23].
Thus, in the presence of sympathetic nerve fibers in the
tissue, norepinephrine would inhibit many proinflamma-
tory activities of neutrophils and monocytes via β2-adre-
noceptors, which might also play a role in synovial tissue
of patients with OA and RA. However, in inflamed syn-
ovial tissue of patients with RA, sympathetic nerve fibers
are lost and replaced by catecholamine-producing cells
[24]. The remaining catecholamine concentrations are
low in the synovial tissue, leading to concentrations suit-
able only for α-adrenergic signaling [24]. Although nor-
epinephrine through α-adrenergic signaling stimulates
proinflammatory factors in neutrophils and macrophages
[21-23], these low concentrations may well play a proin-
flammatory role in inflamed tissue.
By using synovial cells of patients with RA, we investi-
gated the effect of norepinephrine on abundance of the
proinflammatory bactericidal proteins HNP1-3. Experi-
ments were also carried out in cells from OA patients
because possible differences might represent one factor
for the differential effects on bone (erosions in RA versus
formation of new bone in OA). For comparison, we inves-
tigated the human defensin β-defensin 2 (HBD 2). TNF
was used as another important proinflammatory stimulus
to influence defensin secretion for comparison. In addi-
tion, the study aimed to investigate the influence of corti-
sol alone or together with norepinephrine because
cooperative antiinflammatory effects of cortisol and nor-
epinephrine have been described [25].
Materials and methods
Patients
In this investigation, we included 10 patients with OA
and seven patients with RA. Diagnosis of RA was based
on the established criteria according to the American
College of Rheumatology (formerly, the American Rheu-
matism Association) [26]. The characteristics of patients
are given in Table 1. Erythrocyte sedimentation rate and
serum levels of C-reactive protein were measured by
using standard techniques.
The study was approved by the Ethics Committee of the
University of Regensburg. Patients were informed about
the purpose of the study and gave written consent.
Synovial tissue preparation, isolation, and culture of 
primary mixed synovial cells
OA and RA patients underwent elective knee-joint
replacement surgery. Synovial tissue samples were
obtained immediately after opening the knee-joint cap-
sule, preparation of which was described [24]. In brief, a
piece of synovial tissue of ≤9 cm2 was dissected. A larger
piece of the synovial tissue was used to isolate mixed syn-
ovial cells (for culture experiments, see later). Approxi-
mately eight pieces of the same synovial area were used
for immunohistochemistry and immunofluorescence,
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ered saline (PBS) containing 4% formaldehyde and then
incubated in PBS with 20% sucrose for 12 to 24 hours.
Thereafter, they were placed in protective freezing
medium and quick-frozen (Tissue Tek; Sakura Finetek,
Zoeterwoude, The Netherlands). All tissue samples were
stored at 80°C.
For culture experiments, mixed synovial cells were iso-
lated during the morning hours by enzymatic digestion
for 1 to 2 hours at 37°C by using Liberase (Roche Applied
Science, Mannheim, Germany). At approximately 2 to 4
p.m., the synovial cells were resuspended in RPMI 1640
medium (Sigma, Taufkirchen, Germany), supplemented
with 1% penicillin/streptomycin (Life Technologies, Inc.,
Paisley, U.K.) and 0.1% amphotericin B (Bristol-Myers
Squibb, Munich, Germany). In total, 2.5 × 105 isolated
synovial cells of OA or RA patients were incubated for 24
hours in the presence of 200 μM L-ascorbic acid, together
with norepinephrine, TNF, cortisol, or norepinephrine
plus cortisol in indicated concentrations (all substances
from Sigma, Steinheim, Germany).
The percentage of different types of synovial cells was
tested by specific antibodies against prolyl 4 hydroxylase
(for the synoviocyte type B, fibroblasts; Calbiochem, Bad
Soden, Germany), CD163 (synoviocyte type A, mac-
rophages; Dako, Hamburg, Germany), CD3 (T cells;
Dako), CD19 (B lymphocytes; Dako) neutrophils
(elastase; Fitzgerald Industries Int. Inc., Acton, MA,
USA), and mast cells (tryptase; Abcam, Cambridge, UK).
In preliminary experiments with primary early-culture
mixed synoviocytes, we detected that ~37% were positive
for prolyl 4 hydroxylase, 26% for CD163, 12% for CD3, 5%
for CD19, 10% for elastase, and <1% for tryptase.
Immunohistochemistry and double immunofluorescence
Approximately ten 5-μm sections were cut from the fro-
zen tissue blocks. For immunohistochemistry with alka-
line phosphatase as the enzyme system, sections were
blocked with 20% acetic acid for 20 minutes at 4°C. Sec-
tions were further blocked with 10% bovine serum albu-
min, 10% fetal calf serum, and 10% chicken serum for 45
minutes (all from Sigma). Then, sections were incubated
with either monoclonal mouse anti-human antibodies
against HNP1-3 (BMA Biomedicals, Augst, Switzerland,
no. T 1034; dilution, 1:1,000; these antibodies recognize
HNP-1 to -3) or polyclonal rabbit anti-human antibodies
against HBD-2 (Biologo, Kronshagen, Germany, no.
DEF002; dilution, 1:100). Both primary antibodies were
incubated overnight at 4°C. After intensive washing with
phosphate-buffered saline, sections were incubated with
secondary antibodies for 1 hour at room temperature (for
HNP1-3, goat anti-mouse coupled to alkaline phos-
phatase; Dako, no. D0486; dilution, 1:100; for HBD-2,
goat anti-rabbit coupled to alkaline phosphatase, Dako,
no. D0487; dilution, 1:100). The sections were developed
by using BCIP/NBT substrate (Dako, K0598). We con-
trolled specific staining by using irrelevant primary anti-
bodies or serum or by omitting the primary antibody.
Double immunofluorescence was carried out with fixed
frozen tissue and a similar blocking procedure to that
Table 1: Patient characteristics
Osteoarthritis Rheumatoid arthritis
Number 10 7
Age (years) 62.8 ± 3.2 57.0 ± 4.0
Sex (f/m) 6/4 4/3
C-reactive protein (mg/L) 5.1 ± 1.3 25.9 ± 14.1#
Erythrocyte sedimentation rate (mm) 11.5 ± 1.5 27.6 ± 3.1*
Lining layer thickness, cells 2.0 ± 0.5 2.5 ± 0.2
Cellular density (all cells), cells/mm2 364 ± 169 635 ± 329
T-cell density, cells/mm2 1.1 ± 0.1 1.9 ± 0.5
Macrophage density, cells/mm2 55 ± 38 52 ± 16
Medication
Prednisolone (%) N.A. 86.0
Daily prednisolone (mg/day) N.A. 6.1 ± 1.7
Methotrexate (%) N.A. 71.0
Leflunomide (%) N.A. 14.0
Nonsteroidal antiinflammatory drugs (%) 70.0 71.0
Data are given as mean ± SEM. *P < 0.05; #P < 0.005 for the comparison with osteoarthritis. Abbreviations: N.A., not applicable.
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antibodies of BMA Biomedicals and Biologo were used in
the same dilution as given earlier. For double staining,
respective antibodies were used against activated mac-
rophages (CD163, Dako), T lymphocytes (CD3, Dako),
fibroblasts (prolyl-4 hydroxylase, Dako), B lymphocytes
(CD19, Dako), mast cells (tryptase; Abcam, Cambridge,
UK), and neutrophils (elastase; Fitzgerald Industries
International; and Lab Vision NeoMarkers via Thermo
Scientific, Dreieich, Germany). Fluorescent staining of
positive cells was achieved by incubating the sections
with respective secondary Alexa Fluor 488 and 546 anti-
bodies or F(ab')2 fragments (Molecular Probes via Invitro-
gen, Karlsruhe, Germany). Nuclei were stained with
Vectashield mounting medium with DAPI (Vector Labo-
ratories via Biozol, Eching, Germany). We controlled spe-
cific staining by using irrelevant primary antibodies or
serum or by omitting the primary antibody.
Determination of HNP1-3 and HBD-2 in supernatants of 
synovial cells
HNP1-3 were measured with commercially available
ELISA (HyCult Biotechnology, Uden, The Netherlands;
this ELISA recognizes HNP-1 to -3). The detection limit
of this assay was 20 pg/ml. Intra- and interassay coeffi-
cient of variation were <10%.
With respect to HBD-2, a new ELISA was established
by using two commercially available antibodies (capture:
Biologo, no. DEF002, polyclonal rabbit anti-human anti-
bodies; dilution, 1:1,000; detection, R&D Systems, Wies-
baden, Germany; AF2758, polyclonal goat anti-human
antibodies; dilution, 1:200). After overnight coating with
the capture antibody at 4°C, extensive washing, and
blocking with 10% fetal calf serum, 100 μl of standard
(recombinant HBD-2; Dianova, Hamburg, Germany, no.
CYT-26732) or 100 μl supernatant of synovial cells was
incubated for 2 hours at room temperature. After exten-
sive washing, the detection antibody was added for
another hour (at room temperature). After extensive
washing, a rabbit anti-goat tertiary antibody was used,
coupled to biotin (Dako, Hamburg, Germany; no. E0466).
By using streptavidin coupled to horseradish peroxidase
and tetramethylbenzidine (TMB) as the substrate, the
ELISA was developed. The detection limit of this assay
was ~8 pg/ml. Intra- and interassay coefficients of varia-
tion were <15%.
Superfusion technique of synovial tissue
As described in detail earlier [24], we used a microsuper-
fusion-chamber apparatus to superfuse pieces of synovial
tissue with culture medium. This technique allows the
determination of spontaneous defensin release directly
from fresh synovial tissue. The superfusion chambers had
a volume of ~80 μl. Super-fusion was performed for 6
hours at a tempera-ture of 37°C and a flow rate of 66 μl/
min. Synovial tissue pieces had a standard size of 5 μm in
diameter with a precision biopsy punch (Stiefel, Offen-
bach, Germany). Every hour, superfusate was collected to
measure HNP1-3 and HBD-2, as described earlier.
Presentation of the data and statistical analysis
All data are given as mean ± SEM. Box plots give the 10th,
75th, 50th (median), 25th, and 10th percentile. Group medi-
ans were compared by using the nonparametric Mann-
Whitney test (SPSS/PC, Advanced Statistics, V15.0, SPSS
Inc., Chicago, IL, USA). A value of P < 0.05 was the signif-
icance level.
Results
Immunohistochemical localization of HNP1-3 and HBD-2 
and double immunofluorescence
To study the localization of defensins, immunohis-
tochemistry of the synovial lining and sublining area was
performed in patients with OA and RA. A representative
staining of an RA patient is given in Figure 1. HNP1 3
were detected mainly in the synovial lining and in the
directly adjacent sublining area (Figure 1, left panels).
HNP1-3 were present in most of the RA patients and OA
patients. This was quite different for HBD-2, which was
Figure 1 Immunohistochemistry of human neutrophil peptides 
1-3 (HNP1-3) and human β-defensin 2 (HBD 2) in the synovial lin-
ing and sublining area of an RA patient (similar in OA patients). 
Antibodies to HNP1-3 stained positive in the lining and adjacent sub-
lining area, whereas HBD-2 was found only in deep sublining zones. 
Magnification 400×.
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Figure 1, right panels, is a rare example of an RA patient
in whom HBD-2-positive cells were detected in the sub-
lining zone.
In further extensive double immunofluorescence stud-
ies, we provide evidence that HNP1-3 were colocalized to
elastase-positive neutrophils (Figure 2, left panels).
HNP1-3 were not detected in macrophages, fibroblasts, T
lymphocytes, B lymphocytes, or mast cells. Similar to
that in immunohistochemistry, HBD-2 was rarely
detected with immunofluorescence. In these cases, HBD-
2 was colocalized with prolyl-4 of fibroblasts and CD19 of
B lymphocytes (Figure 2, right panels). No similar colo-
calization was observed for macrophages, T lympho-
cytes, neutrophils, or mast cells.
HNP1-3 and HBD-2 from synovial tissue and synovial cells
To study the release of HNP1-3 or HBD-2, the protein
was detected in the superfusate of synovial tissue. Syn-
ovial tissue released HNP1-3, which was particularly evi-
dent in RA patients (Figure 3A). The slow decline of
superfusate concentration is typical for a washout of the
protein and not for a decrease in secretion or production
(Figure 3a). Compatible with the findings in immunohis-
tochemistry, HBD-2 superfusate levels were lower, as
substantiated in RA and OA patients (Figure 3b).
On a very different time scale, levels of defensins were
studied in supernatants of cultured mixed synovial cells
(Figure 3c). The levels of HNP1-3 increased over time,
whereas HBD-2 was barely detectable (Figure 3c, com-
pare detection limits with those in Figure 3a, b). Because
HNP1-3 were detectable by ELISA, further functional
studies included only these peptides. We studied early
HNP1-3 appearance within 24 hours to minimize a possi-
ble effect by necrosis or apoptosis of these cells.
Density of neutrophils in synovial tissues of patients with 
OA and RA
The presence of HNP1-3 prompted us to study the den-
sity of elastase-positive neutrophils in synovial tissues of
Figure 2 Double immunofluorescence of human neutrophil pep-
tides 1-3 (HNP1-3) and human β-defensin 2 (HBD 2) in synovial 
tissue of an RA patient. Arrowheads show double-positive cells. Left 
panels: HNP1-3 (red staining) were co-localized with neutrophil 
elastase (green staining), as indicated by the yellow color in this overlay 
image. Right panels: HBD-2 (red fluorescence) was rarely detected. 
Some fibroblasts (green fluorescence in the upper right panel) and 
some CD19+ B lymphocytes (green fluorescence in the lower right 
panel) stained positive for HBD-2 (yellow overlay). Magnification 400×.
Figure 3 Secretion of defensins from synovial tissue/cells and 
density of synovial neutrophils. (a) Levels of human neutrophil pep-
tides 1-3 (HNP1-3) in superfusate of synovial tissue of two patients with 
rheumatoid arthritis (RA) and osteoarthritis (OA) (four replicates per pa-
tient). The dotted line indicates the detection limit. (b) Levels of human 
β-defensin-2 (HBD 2) in supernatant of synovial tissue of two patients 
with RA and OA (four replicates per patient). The dotted line indicates 
the detection limit. (c) Levels of defensins in supernatant of cultured 
mixed synovial cells over time. Compare the levels with the detection 
levels in panels (a) and (b). After 20 hours, HNP1-3 were in the detect-
able range, which was not the case for HBD-2. The data of four OA pa-
tients are given (two replicates of every patient), which was similar in 
RA patients (data not shown). (d) Density of synovial neutrophils in RA 
and OA synovial tissue. Every symbol represents the average density of 
neutrophils of one patient, as measured in 17 high-power fields (400×) 
of two to three synovial tissue sections, including deep sublining areas.
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higher in RA as compared with OA patients (Figure 3d).
The relatively low density of neutrophils is due to the fact
that neutrophils were present mainly in the lining and
adjacent sublining area but not in deeper layers of the
synovial tissue, which were also considered in calculating
tissue density (see legend in Figure 3d).
Influence of TNF, norepinephrine, and cortisol on levels of 
HNP1-3
To study important factors that might influence HNP1-3
levels, such as proinflammatory cytokines like TNF, this
cytokine was used in culture experiments with mixed
synoviocytes. TNF slightly decreased HNP1-3 levels in
the supernatant of OA cells, which was significant at 1
ng/ml (Figure 4). In RA synoviocytes, TNF did not exert a
similar U-formed dose-response effect because no signif-
icant differences were observed (Figure 4).
In contrast, norepinephrine decreased supernatant
HNP1-3 levels produced by mixed synovial tissue cul-
tures in both OA and RA patients (Figure 5a, b). It is obvi-
ous that this inhibition was present only at high
concentrations when norepinephrine exerts its effects
mainly via β-adrenoceptors (Figure 5a, b).
In OA patients, cortisol at high concentrations of 10-6
M reduced HNP1-3 concentrations (Figure 5c), which
was not observed in RA patients (Figure 5d). In addition,
the combination of cortisol plus norepinephrine led to a
decrease of HNP1-3 levels produced by mixed synovial
tissue cultures in OA and also in RA patients (Figure 5c,
d). However, the combined effect of the two hormones
did not exceed the individual effects of norepinephrine
alone.
Discussion
This study demonstrates the presence of two human
defensins in the synovial tissue of patients with OA and
RA. The α-defensin HNP1-3 and the β-defensin HBD-2
were present in synovial tissue, whereas HNP1-3 was
undoubtedly allocated to neutrophils (we have not tested
for dendritic cells). HBD-2 was found in a small number
of fibroblasts and B lymphocytes. Although HNP1-3 were
easily detectable by using histologic techniques or in cul-
ture experiments, HBD 2 was barely visible in tissue and
measurable in supernatants. This study further demon-
strated that norepinephrine inhibited HNP1 3 in both RA
and OA patients' mixed synovial cell cultures, and corti-
sol and TNF slightly inhibited this α-defensin only in OA
patients. This investigation adds to the understanding of
how the SNS might influence HNP1-3 in chronic inflam-
matory joint diseases.
Figure 4 Influence of tumor necrosis factor (TNF) on levels of hu-
man neutrophil peptides 1-3 (HNP1-3) of mixed synoviocytes. The 
data are derived from five OA and five RA patients (two replicates of ev-
ery patient). Control HNP1-3 levels were 58.3 ± 7.0 pg/ml in OA pa-
tients and 147.2 ± 37.5 pg/ml in RA patients.
Figure 5 Influence of norepinephrine (NE) and cortisol (Cort) on 
human neutrophil peptides 1-3 (HNP1-3) levels in patients with 
rheumatoid arthritis (RA) and osteoarthritis (OA). (a, b) Influence 
of norepinephrine on HNP1-3 levels in supernatants of mixed synovio-
cytes. The data are derived from five OA and five RA patients (two rep-
licates of every patient). Control HNP1-3 values were as described in 
the legend of Figure 4. (c, d) Influence of cortisol or norepinephrine 
plus cortisol on HNP1-3 levels in supernatants of mixed synoviocytes. 
The data are derived from nine OA and seven RA patients (three repli-
cates of every patient). Control HNP1-3 levels were 160.2 ± 50.3 pg/ml 
in OA patients and 73.5 ± 19.9 pg/ml in RA patients.
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cells was demonstrated in the synovial lining of healthy
subjects and in patients with suppurative arthritis, OA,
and RA [8]. However, these authors did not study the reg-
ulation of HNP1-3, which was a particular aspect in the
present work. Another study reported very high synovial
fluid levels of HNP1 3 in RA patients, associated with
more-severe erosions [9]. Because we used the same
ELISA mentioned in the latter study, we were surprised
that our superfusate and supernatant levels of HNP1-3
were lower. We interpret these earlier findings of Bokar-
eva et al. [9] insofar as HNP1-3 accumulate in the syn-
ovial fluid, which has been demonstrated for other
factors as well (for example, estrogens [27]). Because we
have not studied synovial fluid levels, we cannot directly
compare the results of the two studies. However, discrep-
ant findings might also depend on increased abundance
of neutrophils in synovial fluid, as compared with syn-
ovial tissue.
Although HNP1-3 defensins have been reported to be
expressed by granulocytes in synovial tissue [8], it was
not clear whether these proteins are actually released in
the tissue. By using the superfusion approach, we were
able to demonstrate that these proteins are released by
few granulocytes in synovial tissue. In the present study,
HNP1-3 is produced in higher amounts in RA than in
OA, which might reflect the overall greater inflammation
in patients with chronic RA. This is particularly relevant
because RA patients were treated with prednisolone and
antiproliferative drugs that should have reduced proin-
flammatory factors like HNP1-3. HNP1-3-positive cells
were elastase-positive neutrophils, and we can exclude
that other cells such as macrophages, fibroblasts, T and B
lymphocytes, or mast cells stain positive for this protein.
However, we have not tested dendritic cells that can also
produce HNP1-3 [10,11]. The relatively low number of
neutrophils in the tissue might be a consequence of rapid
migration into the synovial fluid (>95% are neutrophils).
The mentioned first study of Paulsen et al. also
reported on HBD-2 [8], which was not found in their
samples investigated (they found the defensins HBD-3,
CAP37, and LL37). We confirmed that immunohistologic
detection of HBD-2 is a rare event (found in only one
patient with RA and in one with OA). Nevertheless, this
RA patient had numerous positive cells that allowed dou-
ble staining, revealing double-positive fibroblasts and B
lympho-cytes. Because HBD-2 levels were below the
detection limit in most superfusate and supernatant sam-
ples, functional experiments with TNF and hormones
aimed only to investigate the α-defensin HNP1-3. Further
studies corroborated that neutrophils are present in OA
and RA tissue, and that the density of these cells is higher
in RA than in OA patients. It is known that the SNS has a
strong influence on neutrophils (but also on monocytes),
so we were particularly interested in the functional
effects of the SNS on HNP1-3.
The major neurotransmitter of sympathetic nerve
fibers, norepinephrine, inhibits several cellular functions.
For example, norepinephrine decreases migration
[17,18], oxygen radical production [19], phagocytosis
[18], and bactericidal activity [20]. These inhibitory influ-
ences on neutrophils (but also on monocytes) were pres-
ent only when norepinephrine appeared at high
concentrations (via β2-adrenergic receptors). This might
be quite different at low concentrations, when norepi-
nephrine exerts its effects via α-adrenoceptors [21-23].
Our present study supports the inhibitory influence of
norepinephrine, focusing on the α-defensin HNP1-3. In
both RA and OA patients, norepinephrine dose-depend-
ently decreased supernatant levels of HNP1-3 from
mixed synovial tissue cultures, which reached the signifi-
cance level only at high concentrations. These norepi-
nephrine effects were stronger when compared with
cortisol alone, which did not influence HNP1-3 in RA
synovial cells. In addition, the combination of norepi-
nephrine plus cortisol did not materialize in an additive
or even synergistic effect. These results confirm the over-
all inhibitory effect of norepinephrine on cellular func-
tions, given that concentrations of this neurotransmitter
are high enough. At low concentrations of 10-9 M norepi-
nephrine, we did not observe opposite effects that would
indicate a proinflammatory influence on mixed synovial
tissue cultures via α-adrenoceptors.
Because TNF is an important proinflammatory mole-
cule in chronic inflammatory joint diseases, the effect of
this cytokine on HNP1-3 levels was tested in this study. It
was known that β-defensins such as HBD-2 can be stimu-
lated by TNF in epithelial cells and astrocytes [28,29],
but, to our knowledge, effects of TNF on HNP1-3 were
not investigated (especially not in OA/RA material). TNF
decreased HNP1-3 supernatant levels in OA mixed syn-
ovial cultures, and the dose-response curve was U-
shaped with a maximum inhibition at 1.0 ng TNF/ml.
TNF did not exert similar effects in RA cell cultures,
which may be related to already high TNF levels in these
cell preparations (receptor desensitization). Because,
conversely, HNP1-3 can stimulate TNF secretion from
macrophages, as recently reported [7], the TNF-induced
inhibition of HNP1-3 might be part of a negative-feed-
back loop that prevents overshooting of innate immune
responses. From this point of view, we hypothesize that
HNP1-3 precedes TNF in the stimulatory cascade of
innate immunity events. This would be an important
aspect because TNF has been installed at the forefront of
the innate immunity cascade in RA [30].
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In conclusion, HNP1-3 is present in neutrophils, and as
compared with HBD-2, it is abundantly present in chron-
ically inflamed synovial tissue of patients with RA and
OA. Because HNP1-3 levels are decreased by norepi-
nephrine in mixed synovial-cell cultures, this study dem-
onstrates that the SNS might inhibit neutrophil (but also
monocyte) function in vivo. Sympathetic nerve fibers are
lost in inflamed tissue [24,31], so concentrations of this
neurotransmitter are probably too low to induce antiin-
flammatory activities. A similar situation exists for TNF,
which is also decreased by norepinephrine [32]. HNP1-3
can stimulate secretion of TNF [7], so the loss of sympa-
thetic nerve fibers with low concentrations of norepi-
nephrine might have double-negative effects, possibly
increasing both local HNP1-3 and TNF levels. This sce-
nario can be relevant in overt inflammation of the tissue
when monocytes (HNP1-3, TNF), macrophages (TNF),
and neutrophils (HNP1-3) play a decisive role.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BR and SG participated in the concept and design and acquisition of data. RW
and MF participated in interpretation of data and in drafting and revising the
article. RHS participated in the concept and design, analysis and interpretation
of data, and drafting and revising the article.
Acknowledgements
The authors thank Dr. Sven Anders and Dr. Joachim Grifka for kindly supplying 
synovial tissue.
This study was supported by a grant from the Deutsche Forschungsgemein-
schaft (Research Unit FOR696).
Author Details
1Laboratory of Experimental Rheumatology and Neuroendocrino-
Immunology, Division of Rheumatology, Department of Internal Medicine I, 
University Hospital, F.J. Strauss Allee 11, 93053 Regensburg, Germany and 
2Department of Orthopedic Surgery, University Hospital Regensburg, 
Asklepios Clinic Bad Abbach, Kaiser-Karl-V.-Allee 3, 93077 Bad Abbach, 
Germany
References
1. Liu H, Pope RM: Phagocytes: mechanisms of inflammation and tissue 
destruction.  Rheum Dis Clin North Am 2004, 30:19-39.
2. Eyles JL, Roberts AW, Metcalf D, Wicks IP: Granulocyte colony-stimulating 
factor and neutrophils: forgotten mediators of inflammatory disease.  
Nat Clin Pract Rheumatol 2006, 2:500-510.
3. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: 
Defensins. Natural peptide antibiotics of human neutrophils.  J Clin 
Invest 1985, 76:1427-1435.
4. Defensins Knowledgebase   [http://defensins.bii.a-star.edu.sg/]
5. Lehrer RI: Primate defensins.  Nat Rev Microbiol 2004, 2:727-738.
6. Menendez A, Brett FB: Defensins in the immunology of bacterial 
infections.  Curr Opin Immunol 2007, 19:385-391.
7. Soehnlein O, Kai-Larsen Y, Frithiof R, Sorensen OE, Kenne E, Scharffetter-
Kochanek K, Eriksson EE, Herwald H, Agerberth B, Lindbom L: Neutrophil 
primary granule proteins HBP and HNP1-3 boost bacterial 
phagocytosis by human and murine macrophages.  J Clin Invest 2008, 
118:3491-3502.
8. Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, Petersen W: 
Antimicrobial peptides are expressed and produced in healthy and 
inflamed human synovial membranes.  J Pathol 2002, 198:369-377.
9. Bokarewa MI, Jin T, Tarkowski A: Intraarticular release and accumulation 
of defensins and bactericidal/permeability-increasing protein in 
patients with rheumatoid arthritis.  J Rheumatol 2003, 30:1719-1724.
10. Mackewicz CE, Yuan J, Tran P, Diaz L, Mack E, Selsted ME, Levy JA: alpha-
Defensins can have anti-HIV activity but are not CD8 cell anti-HIV 
factors.  AIDS 2003, 17:F23-F32.
11. Rodriguez-Garcia M, Climent N, Oliva H, Casanova V, Franco R, Leon A, 
Gatell JM, Garcia F, Gallart T: Increased alpha-defensins 1-3 production 
by dendritic cells in HIV-infected individuals is associated with slower 
disease progression.  PLoS One 2010, 5:e9436.
12. Straub RH, Härle P: Sympathetic neurotransmitters in joint 
inflammation.  Rheum Dis Clin North Am 2005, 31:43-59.
13. Härle P, Mobius D, Carr DJ, Schölmerich J, Straub RH: An opposing time-
dependent immune-modulating effect of the sympathetic nervous 
system conferred by altering the cytokine profile in the local lymph 
nodes and spleen of mice with type II collagen-induced arthritis.  
Arthritis Rheum 2005, 52:1305-1313.
14. Berkow RL, Dodson RW: Functional analysis of the marginating pool of 
human polymorphonuclear leukocytes.  Am J Hematol 1987, 24:47-54.
15. Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M: Catecholamine-
induced leukocytosis: early observations, current research, and future 
directions.  Brain Behav Immun 1996, 10:77-91.
16. Kappel M, Poulsen TD, Galbo H, Pedersen BK: Effects of elevated plasma 
noradrenaline concentration on the immune system in humans.  Eur J 
Appl Physiol Occup Physiol 1998, 79:93-98.
17. Doukas J, Hechtman HB, Shepro D: Vasoactive amines and eicosanoids 
interactively regulate both polymorphonuclear leukocyte diapedesis 
and albumin permeability in vitro.  Microvasc Res 1989, 37:125-137.
18. Gosain A, Gamelli RL, DiPietro LA: Norepinephrine-mediated 
suppression of phagocytosis by wound neutrophils.  J Surg Res 2009, 
152:311-318.
19. Trabold B, Gruber M, Frohlich D: Functional and phenotypic changes in 
polymorphonuclear neutrophils induced by catecholamines.  Scand 
Cardiovasc J 2007, 41:59-64.
20. Qualliotine D, DeChatelet LR, McCall CE, Cooper MR: Effect of 
catecholamines on the bactericidal activity of polymorphonuclear 
leukocytes.  Infect Immun 1972, 6:211-217.
21. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire 
SR, List RP, Day DE, Hoesel LM, Gao H, Van RN, Huber-Lang MS, Neubig RR, 
Ward PA: Phagocyte-derived catecholamines enhance acute 
inflammatory injury.  Nature 2007, 449:721-725.
22. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL: Stimulation of 
alpha-adrenergic receptor augments the production of macrophage-
derived tumor necrosis factor.  J Immunol 1990, 145:1430-1434.
23. Flierl MA, Rittirsch D, Nadeau BA, Sarma JV, Day DE, Lentsch AB, Huber-
Lang MS, Ward PA: Upregulation of phagocyte-derived catecholamines 
augments the acute inflammatory response.  PLoS One 2009, 4:e4414.
24. Miller LE, Jüsten HP, Schölmerich J, Straub RH: The loss of sympathetic 
nerve fibers in the synovial tissue of patients with rheumatoid arthritis 
is accompanied by increased norepinephrine release from synovial 
macrophages.  FASEB J 2000, 14:2097-2107.
25. Straub RH, Günzler C, Miller LE, Cutolo M, Schölmerich J, Schill S: Anti-
inflammatory cooperativity of corticosteroids and norepinephrine in 
rheumatoid arthritis synovial tissue in vivo and in vitro.  FASEB J 2002, 
16:993-1000.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, 
Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism 
Association 1987 revised criteria for the classification of rheumatoid 
arthritis.  Arthritis Rheum 1988, 31:315-324.
27. Castagnetta LA, Carruba G, Granata OM, Stefano R, Miele M, Schmidt M, 
Cutolo M, Straub RH: Increased estrogen formation and estrogen to 
androgen ratio in the synovial fluid of patients with rheumatoid 
arthritis.  J Rheumatol 2003, 30:2597-2605.
28. Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, 
Schroder JM: Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-
1beta, but not IL-6, induce human beta-defensin-2 in respiratory 
epithelia.  Am J Respir Cell Mol Biol 2000, 22:714-721.
29. Hao HN, Zhao J, Lotoczky G, Grever WE, Lyman WD: Induction of human 
beta-defensin-2 expression in human astrocytes by lipopolysaccharide 
and cytokines.  J Neurochem 2001, 77:1027-1035.
Received: 26 January 2010 Revised: 24 March 2010 
Accepted: 4 June 2010 Published: 4 June 2010
This article is available from: http://arthritis-research.com/content/12/3/R110© 2010 Ri pl et l.; lic nsee BioMed Central Ltd. is an o en ccess a ticle distribu d und r the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Arthritis R search & Therapy 2010, 12:R110
Riepl et al. Arthritis Research & Therapy 2010, 12:R110
http://arthritis-research.com/content/12/3/R110
Page 9 of 930. Brennan FM: The inflammatory cytokine cascade.  Arthritis Rheum 1999, 
42:S32.
31. Weidler C, Holzer C, Harbuz M, Hofbauer R, Angele P, Scholmerich J, 
Straub RH: Low density of sympathetic nerve fibres and increased 
density of brain derived neurotrophic factor positive cells in RA 
synovium.  Ann Rheum Dis 2005, 64:13-20.
32. Spengler RN, Chensue SW, Giacherio DA, Blenk N, Kunkel SL: Endogenous 
norepinephrine regulates tumor necrosis factor-alpha production 
from macrophages in vitro.  J Immunol 1994, 152:3024-3031.
doi: 10.1186/ar3044
Cite this article as: Riepl et al., Tumor necrosis factor and norepinephrine 
lower the levels of human neutrophil peptides 1-3 secretion by mixed syn-
ovial tissue cultures in osteoarthritis and rheumatoid arthritis Arthritis 
Research & Therapy 2010, 12:R110
